- Conditions
- Solid Tumors
- Interventions
- RO7444973, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 101
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
- Interventions
- Anakinra, Tocilizumab, Standard medical treatment
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Glofitamab, Obinutuzumab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 940 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more
- Conditions
- Lymphoma
- Interventions
- Glofitamab, Tocilizumab, Obinutuzumab, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 17
- States / cities
- La Jolla, California • Laguna Hills, California • Newport Beach, California + 14 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 11 Years to 12 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tocilizumab, Placebo to tocilizumab, Methotrexate, Placebo to methotrexate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 61
- States / cities
- Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 54 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Basal Cell Carcinoma
- Interventions
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy, Recombinant Flt3 Ligand, Pembrolizumab, Tocilizumab
- Biological · Drug · Radiation
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer, Liver Metastases
- Interventions
- RO7119929, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Immune-related Adverse Events, Advanced Solid Tumor
- Interventions
- Rituximab, Tocilizumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, tocilizumab [RoActemra/Actemra]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 76
- States / cities
- Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 71 more
- Conditions
- Dermatomyositis, Polymyositis
- Interventions
- tocilizumab, placebo
- Drug
- Lead sponsor
- Chester Oddis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Kansas City, Kansas • Rochester, Minnesota + 4 more
- Conditions
- CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Small Lymphocytic Lymphoma
- Interventions
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Tocilizumab
- Biological · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Up to 24 Months
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 9
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Louisville, Kentucky + 5 more
- Conditions
- B-cell Non-Hodgkin Lymphoma
- Interventions
- Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 12 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 12
- States / cities
- Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more
- Conditions
- Relapsed or Refractory Follicular Lymphoma
- Interventions
- Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 17
- States / cities
- Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab [RoActemra/Actemra], methotrexate, placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 556 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 21
- States / cities
- Santa Monica, California • Upland, California • Whittier, California + 18 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Etanercept, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 3,080 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 125 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc, Placebo iv
- Biological · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 74
- States / cities
- Mesa, Arizona • Paradise Valley, Arizona • Scottsdale, Arizona + 66 more
- Conditions
- Hematologic Malignancy, Bone Marrow Transplant
- Interventions
- Tocilizumab, Fludarabine, Melphalan, Anti-thymocyte globulin (rabbit), Total Body Irradiation
- Drug · Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Giant Cell Arteritis (GCA)
- Interventions
- Tocilizumab, Discontinue Tocilizumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 4 more
- Conditions
- COVID-19
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Chicago, Illinois • Mount Pleasant, Michigan + 4 more
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Tocilizumab, Placebo
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab [RoActemra/Actemra], Placebo, Methotrexate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 57 more